How Hydrochlorothiazide Affects Gout
Hydrochlorothiazide increases the risk of gout by decreasing uric acid excretion, and should be switched to an alternative antihypertensive agent when feasible in patients with gout. 1
Mechanism of Action
Hydrochlorothiazide directly impairs renal uric acid excretion. The FDA drug label explicitly states that hydrochlorothiazide "decreases the excretion of calcium and uric acid" 2. This pharmacologic effect elevates serum urate concentrations, creating the biochemical environment for monosodium urate crystal formation and deposition in joints.
Clinical Evidence of Gout Risk
The magnitude of risk is substantial and dose-dependent:
- Current thiazide use increases gout risk by 70% (adjusted OR 1.70,95% CI 1.62-1.79) compared to past use 3
- Doses ≥25 mg/day of hydrochlorothiazide significantly increase risk for initiating anti-gout therapy (RR 1.99-2.29), while lower doses show no significant increase 4
- Loop diuretics confer even higher risk (OR 2.64), and combined thiazide plus loop diuretic use carries the highest risk (OR 4.65) 3
The risk is particularly elevated in specific patient subgroups. Among men taking thiazides, obesity increases gout risk 3.7-fold and high alcohol intake increases risk 3.3-fold 5. Approximately 40% of acute gout episodes in thiazide users could be prevented by avoiding thiazides in men weighing >90 kg or consuming >56 units of alcohol weekly 5.
Guideline-Based Management Recommendation
The 2020 American College of Rheumatology Guideline provides clear direction: "Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity" 1.
Practical Implementation Algorithm:
- Identify all gout patients on hydrochlorothiazide - disease activity status does not matter
- Assess feasibility of switching - consider cardiovascular indications, blood pressure control, other comorbidities
- Preferentially switch to losartan when an antihypertensive is needed, as losartan has modest urate-lowering effects and is conditionally recommended 1
- Consider calcium channel blockers as alternatives, which may slightly attenuate gout risk 3
- Avoid switching to loop diuretics, which carry even higher gout risk than thiazides 3, 5
Important Caveats
Do not stop hydrochlorothiazide if it's being used for an appropriate indication where alternatives are inadequate - the medication change should only occur when the serum urate/gout benefits exceed the potential cardiovascular or other risks 1. This is a conditional recommendation, meaning shared decision-making is essential.
The genetic contribution to gout risk persists even in diuretic users, with serum urate-associated genetic variants conferring similar risk (OR 2.04-2.70 for higher genetic risk scores) regardless of diuretic exposure 6. This means that hydrochlorothiazide acts as an additive risk factor rather than the sole cause - patients with genetic predisposition remain at elevated risk even after switching medications.
Chlorthalidone carries similar gout risk to hydrochlorothiazide at equivalent doses (1.68% vs 1.29%, p=0.27), so switching between these two thiazide-type diuretics provides no benefit 7.